Search Results

 

You need to login or register to view this content

All our reports and results are available free of charge personal use, and/or non-commercial use, however, you must first register with us to view our data.

View full Terms and Conditions



Log In

Respondent CDP 2008: AstraZeneca

General Information
<>It requirement CDP questionnaire introduction answer like text box attach document

 
<>Where available provide following identification numbers primary listings/ordinary shares information company Company Turnover (also known sales) millions US$
29559

 
<>ISIN number
GB0009895292

 
<>CUSIP number
046353108

 
<>SEDOL number
0989529

 
1 - Risks and Opportunities
Question 1(a)(i) Regulatory Risks
<>How company exposed regulatory risks related climate change
We consider our company to be exposed to regulatory risks because... 
Seven AstraZeneca facilities held CO2 emission permits phase EU Emissions Trading Scheme (ETS) total sites received allocations 226 thousand tonnes years phase EU ETS result internal abatement efforts able trade surplus allocation phase generated revenue reinvested energy efficiency inside AZ received lower allocations second phase EU ETS 2008 2012 allowing divestment 2007 seven sites affected existing planned emission abatement activities mean emissions exceed allocations anticipate net purchaser credits meet compliance commitments EUETS Phase II foresee existing reasonably predictable regulatory frameworks EU Energy Performance Buildings Directive UK Carbon Reduction Commitment proposed Lieberman Warner Climate Security (s 2191) USA having significant financial compliance impacts organization far greater importance delivering proactive action mitigate climate change emissions role contributing societal response adaptation especially area healthcare provision changing disease patterns

 
<>Would like provide additional information relating question provided
No 

 
Question 1(a)(ii) Physical Risks
<>How company exposed physical risks climate change
We consider our company to be exposed to physical risks because... 
Currently AstraZeneca felt little actual impact climate disruption combine global capabilities high quality relationships local markets enable respond quickly effectively changing business needs confident rise adaptive challenges presented climate change 67 000 employees operating 100 countries 17 research development centres countries 29 manufacturing sites 20 countries dedicated ensuring deliver secure high quality cost effective supply effective prescription medicines bring benefit patients add value shareholders wider society Climate induced changes disrupt ability operate effectively realise benefits include interruption energy transport infrastructures scarcity water resources disruption key supply chain products services Water resources increasingly limited face climate change manufacturing sites located countries water resources currently classified ‘ highly stressed’ ‘ medium stressed’ UNEP (geodata grid unep ch) 13% total water use globally areas water scarcity recognise responsibility use water wisely protecting ability operate effectively areas China example active programme minimize water use place including efficient use cooling water Similarly India R& D site effluent treatment plant process water recycled 90% used purposes maintaining landscaped garden Australian manufacturing site joined national “ Drop Counts” water minimization programme Mexico consumption fresh water subsequent wastewater emissions reduced use reverse osmosis Water does meet quality standards used non process non potable purposes

 
<>Would like provide additional information relating question provided
No 

 
Question 1(a)(iii) General Risks
<>How company exposed general risks result climate change
We consider our company to be exposed to general risks because... 
AstraZeneca exposed generic risks businesses potential power supply instabilities variable access renewable energy sources disruption interruption key supply chains Climate change bring impacts specific relevance AstraZeneca pharmaceutical industry increasingly recognised climate change just environmental issue affects health livelihood millions people relationship climate change health extremely complex indirect direct impacts peoples’ health evaluated evidence suggests rising temperatures result increases vector water food borne diseases cardio respiratory problems extreme weather events floods storms droughts causing malnutrition social disruption death Disrupted weather systems result drought areas flooding leading malnutrition result reduced agricultural productivity supply chain failures Flooding impact sanitation clean water supplies contaminating water leading array gastrointestinal infections increasing incidence water borne diseases malaria cholera affect power supplies infrastructure hampering provision healthcare delaying disaster relief significantly hindering emergency response Climate change affect areas world vulnerability climate change strongly regionally differentiated developed countries tropical subtropical areas susceptible adverse impact dependence natural resources limited ability adapt changing environment poor disproportionably affected resources likely bear greatest burden putting pressure achieving Millennium Development Goals 2015 killer diseases highly sensitive climatic conditions spread conditions change instance recently outbreaks malaria highland regions Kenya steps mitigate situation addressing causes climate change reducing impact environment Individuals communities governments responsibility make necessary policy behaviour changes AstraZeneca takes responsibility seriously sustainability explicitly integrated AstraZeneca’ s Corporate Responsibility Priority Action Plan Key performance indicators targets established climate change waste Furthermore business fighting disease provide medicines help patients physicians combat significant threats life health AstraZeneca consider value medicines patients society heart corporate responsibility effort Innovation drives progress society case pharmaceuticals innovative medicines bring benefits patients improving health quality life millions people worldwide create wealth contribute economic development communities serve

 
<>Would like provide additional information relating question provided
No 

 
Question 1(a)(iv) Risk Management
<>Has company taken planned action manage general regulatory risks and/oradapt physical risks identified
We have taken or planned action. 
continue implement global control framework identification management risks opportunities Senior Executive Team senior managers accountable Corporate Responsibility (CR) risk management areas including emerging risks associated issues like climate change based global framework taking account national functional site issues priorities Individually AstraZeneca responsibility integrate CR considerations day day decision making actions behaviours element complying recently revised Code Conduct 2007 strengthened CR leadership governance establishment new function Group Public Affairs leading development strategic approach aligning tactical delivery new group works closely Global Compliance group senior business functional leaders AstraZeneca ensure appropriate systems place identifying risks opportunities associated corporate responsibility including climate change established cross functional cross territorial Issues Management Council (IMC) monitors external environment new emerging issues relating business affect concern stakeholders team works people issues internally agree appropriate actions timelines possible key performance indicators Vice President Public Affairs chairs IMC member Global Compliance Committee ensure reputational risk fully captured appropriate level

 
<>Would like provide additional information relating question provided
No 

 
Question 1(a)(v) Financial Business implications
<>How assess current and/or future financial effects therisks identified risks affect business
We assess current and/or future financial effects by... 
financial business implications assessed using enterprise wide risk management activities framework described question 1a iv

 
<>Would like provide additional information relating question provided
No 

 
Question 1(b)(i) Regulatory Opportunities
<>How current anticipated regulatory requirements climate change offeropportunities company
We consider that current or anticipated regulatory requirements offer opportunities because... 
opportunities specific AstraZeneca identified related regulatory changes support use create additional incentives improve energy efficiency facilitate dissemination renewable technologies assure power generation capacity supply Mandatory disclosure requirements useful role increasing number consistency climate change related reports published private public sector organisations opportunities largely represented potential reduce operating costs environmental impacts enhance reputation stakeholders

 
<>Would like provide additional information relating question provided
No 

 
Question 1(b)(ii) Physical Opportunities
<>How current anticipated physical changes resulting climate change presentopportunities company
We consider that current or anticipated physical changes offer opportunities because... 
specific opportunities identified related physical changes opportunities largely represented potential reduce operating costs environmental impacts enhance stakeholder acceptability organization

 
<>Would like provide additional information relating question provided
No 

 
Question 1(b)(iii) General Opportunities
<>How does climate change present general opportunities company
We consider that climate change offers opportunities because... 
demand healthcare continues grow driven people living longer rising populations emergence new economies despite significant advances healthcare recent decades diseases remain diagnosed treated effective therapy Alongside opportunities business represented medical societal drivers face number challenges including responsibility react climate induced changes disease patterns healthcare needs AstraZeneca positioned respond changing healthcare needs society business strategy centres strengthening research development pipeline new medicines whilst working improve efficiency development processes ensure medicines patients quickly Underpinning strategy continue promote culture responsibility accountability aspects business activity make interaction count ensuring AstraZeneca continues welcomed trusted member society specific examples approach areas world affected increase respiratory conditions allergies linked increased air pollution pollen potentially skin cancer cataracts linked ozone depletion AstraZeneca pioneered programme Sweden establish dedicated Asthma Treatment Units specially trained staff operating healthcare TB essentially disease poverty treatment regimes complicated prolonged Droughts flooding caused extreme weather events leading crop failures exacerbate fragile economies lead widespread displacement populations disrupted supply lines vital medicines AstraZeneca number initiatives aimed finding new treatments TB helping strengthen healthcare systems provide education training ensure effective supply distribution mechanisms place

 
<>Would like provide additional information relating question provided
No 

 
Question 1(b)(iv) Maximizing Opportunities
<>Do invest plans invest products services designedto minimize adapt effects climate change
Climate change has led to investment or planned investment in order to maximise climate change opportunities. 
small aerosol device called pressurised metered dose inhaler (pMDI) commonly used effective control respiratory diseases brought market inhaled medicine devices lower greenhouse gas content compared original pMDIs CFCs gases used originally pMDIs identified ozone depleting gases worked develop alternatives Turbuhaler dry powder inhaler launched 1987 does require propellant gas suitable patients developed introducing alternative propellant gases pMDIs ozone depletion potential significantly half global warming potential CFCs replace HFA (hydrofluoroalkanes) propellants impact climate change international consensus safer alternative patients global climate (see instance IPCC/TEAP Special report Safeguarding Ozone Layer Global Climate Issues related hydrofluorocarbons perfluorocarbons http //www ipcc ch/pdf/special reports/sroc/sroc08 pdf) 2007 introduced new asthma treatment Symbicort 30 million people suffer debilitating disease new therapy provides rapid effective asthma control pMDI containing HFA propellant

 
<>Would like provide additional information relating question provided
No 

 
Question 1(b)(v) Financial Business Implications
<>How assess current and/or future financial effects theopportunities identified opportunities affect business
We assess current and/or future financial effects by... 
financial business implications assessed using framework described question 1a iv

 
<>Would like provide additional information relating question provided
No 

 
2 - Greenhouse Gas (GHG) Emissions Accounting
Question 2(a)(i) Reporting Boundary
Calculation tools assist companies calculating GHG emissions particular activities combustion fuels production processes http //www ghgprotocol org/calculation tools/all tools Companies new emissions reporting strongly recommended use tools assist calculations used calculation tool list question methodologies
<>Please indicate category best describes company entities groupfor response prepared
Companies over which financial control is exercised – per consolidated audited Financial Statements. 

 
<>Would like provide additional information relating question provided
Yes 
general boundary reporting companies financial control exercised consolidated audited Financial Statements facilities related healthcare business included exception KuDOS Arrow Therapeutics MedImmune including Cambridge Antibody Technology recently acquired AstraZeneca currently working new companies effectively align programmes strategic level time performance included data 2007 turnover new group members $714 million compared $29559 million turnover group indicates data presented covers approx 97 6% group turnover Businesses divested Company merger included date divestment

 
Question 2(a)(ii) Reporting Year
<>Please explicitly state dates accounting year period GHG emissionsare reported
Start date 01 January 2007End date 31 December 2007Financial accounting year 01 January 2007

 
<>Would like provide additional information relating question provided
No 

 
Question 2(a)(iii) Methodology
<>Please specify methodology used company calculate GHG emissions select methodology used using radio buttons used GHG Protocol ISO 14064 1 references calculation tools used explanation calculation methods devised explain data sources Global Warming Potentials emission factors used calculations reference supplied calculation tool contact provider calculation tool information used methodology devised explain methodology including methods calculation data sources Global Warming Potentials emission factors
GHG Protocol 
use internally developed collecting assessing Safety Health Environment performance data majority data needed compile GhG inventory collected accuracy assured global reporting Safety health environmental data received parts AstraZeneca quarterly AZSHE department facility required report performance set criteria defined global reporting procedure Currently 158 submissions data received 107 locations 60 countries attached procedure note details information compiled sources used identifying appropriate emission GWP factors

 
<>Would like provide additional information relating question provided
No 

Download attachment
 
Question 2(b)(i) Scope 1 Scope 2 GHG Protocol
<>Are able provide breakdown direct indirect emissions Scopes 1 2 GHG Protocol analyse electricity consumption

 
<>Would like provide additional information relating question provided
No 

 
Question 2(b)(i)(y) Scope 1 Scope 2 GHG Protocol Year 1 answers
<>Please enter dates reporting period specified (answer question 2(a)(i)) answer questions period selecting “ Add Additional Year Figures” button end webpage repeat process previous reporting period reporting period possible data going reporting period ending 2004 enter historical data reported information response previous CDP questionnaires

 
<>Please enter accounting year used report GHG emissions details
Start date 01 January 2007End date 31 December 2007

 
<>Scope 1 Direct GHG Emissions provide Total global Scope 1 activity Metric Tonnes CO2 e emitted
<>441800 CO2e metric tonnes < text="">

 
<>b Total Scope 1 activity Metric Tonnes CO2 e emitted Annex Bcountries
<>249900 CO2e metric tonnes < text="">

 
<>By country Scope 1 activity metric tonnes CO2 e individual country Using methodology state emissions country NB practical list emissions country country basis list countries significant emissions context business combine remainder “ rest world” information format (e g Excel) attach
Country Scope 1 Emissions
(metric tonnes CO2-e)
Sweden 12700
United Kingdom 154300
USA 45100
Rest World 48100

 
<>Scope 2 Indirect GHG emissions provide c Total global Scope 2 activity metric tonnes CO2 e emitted
<>276200 CO2e metric tonnes < text="">

 
<>d Total Scope 2 activity metric tonnes CO2 e emitted Annex Bcountries
<>208200 CO2e metric tonnes < text="">

 
<>By country Scope 2 activity metric tonnes CO2 e individual country
Country Scope 2 Emissions
(metric tonnes CO2-e)
Sweden 26800
United Kingdom 48400
USA 88000
Rest World 113000

 
<>Electricity consumptione Total global MWh purchased electricity
951300 MWh

 
<>f Total MWh purchased electricity Annex B countries
854400 MWh

 
<>By country – MWh purchased electricity individual country
Country
Sweden 362100
United Kingdom 174400
USA 156900
Rest World 257800

 
<>g Total global MWh purchased electricity renewable sources
221000 MWh

 
<>h Total MWh purchased electricity renewable sources Annex Bcountries
213800 MWh

 
<>By country – MWh purchased electricity renewable sources individual country
Country
Sweden 55100
United Kingdom 145600
USA 3200
Rest World 17100

 
<>Would like provide additional information relating question provided
Yes 
Total global Scope 1 activity metric tonnes CO2 e emitted 441800 tonnes including fossil fuel use process emissions facilities (288000 tonnes) road travel vehicles (153800 tonnes) b Total Scope 1 activity metric tonnes CO2 e emitted Annex B countries 249900 tonnes including fossil fuel use process emissions facilities excluding road travel vehicles c Total global Scope 2 activity metric tonnes CO2 e emitted 276200 tonnes including electricity district heating steam imported parties Data previous reporting periods submitted previous reports CDP

 
Question 2(b)(ii) Scopes 1 2 GHG Protocol
<>If unable Scope 1 Scope 2 GHG emissions and/or electricity consumption report GHG emissions able identify description emissions answered 2(b)(i) question 2(c)(i)

 
<>Would like provide additional information relating question provided
No 

 
Question 2(c)(i) Emissions – Scope 3 GHG Protocol
<>How identify and/or measure Scope 3 emissions

 
<>Please provide possible Details significant Scope 3 sources company
identified business air travel road air freight waste incineration emissions inhalation medicine products use patients major contributors Scope III footprint

 
<>b Details metric tonnes CO2 e GHG emissions following categories Employee business travel
<>62500 CO2e metric tonnes < text="">

 
<>ii External distribution/logistics
<>137900 CO2e metric tonnes < text="">

 
<>iii Use/disposal company’ s products services
<>346300 CO2e metric tonnes < text="">

 
<>iv Company supply chain
<>29000 CO2e metric tonnes < text="">

 
<>c Details methodology use quantify estimate Scope 3 emissions
use WRI/WBCSD Greenhouse Gas Protocol corporate accounting reporting standard build report Scope III emissions inventory Scope III emissions quantified using methodology outlined answer attached file question 2 iii

 
<>Would like provide additional information relating question provided
Yes 
Comment bii External distribution/logistics 137900 tonnes 48 200 tonnes emitted road freight 89 700 tonnes air freight biv Company supply chain 29000 tonnes CO2 emitted waste incineration parties manufacture key intermediates products behalf 2005 working outsourcing partners measure environmental impact manufacture intermediates established pharmaceutical brands produced behalf including waste production CO2 emissions energy use Figures 2007 available CO2 emissions energy used party premises manufacture products amounted 26 000 tonnes 2006

 
Question 2(d) External Verification
<>(i) information reported response Questions 2(b) (c) beenexternally verified audited plan information verified oraudited
Yes (Please go to 2(d)(ii)) 

 
<>(ii) answer question 2d(i) Yes provide attach copy audit verification statement state plans verification
Bureau Veritas verify Corporate Responsibility report content including GhG inventory http //www astrazeneca com/article/511800 aspx

 
<>(iii) specify standard protocol information hasbeen audited verified
assurance process considers accuracy completeness relevance CR content line requirements AA1000 Assurance Standard (AS) assesses AstraZeneca responsive material needs stakeholders 2007 AstraZeneca formally revised approach key performance indicators reported requirements G3 Global Reporting Initiative (GRI) assurance process Bureau Veritas assess AstraZeneca’ s achievement aim concluded 2007 report meets requirements GRI B+ application level

 
<>Would like provide additional information relating question provided
No 

 
Question 2(e) Data Accuracy
<>Does company place assess accuracy GHG emissions inventory calculation methods data processes systems relating GHG measurement provide details explain data accuracy managed
Yes, we do have a system. 
majority data needed compile GhG inventory collected accuracy assured global reporting Safety health environmental data received parts AstraZeneca quarterly AZSHE department facility required report performance set criteria defined global reporting procedure Currently 158 submissions data received 107 locations 60 countries Regular review data carried ensure accuracy consistency lead slight changes statistics produced previous years statistics quoted response generated revised data treatment baseline target reported data accordance guidance held Greenhouse Gas Protocol (WRI/WBCSD 2004 Revised Edition Chapter 5 – Tracking Emissions Time Chapter 7 – Managing Inventory Quality) GRI Sustainability Reporting Guidelines provide advice issue Furthermore accuracy information used reporting internal external sources assured external verification Bureau Veritas (see question 2 d above)

 
<>Would like provide additional information relating question provided
No 

 
Question 2(f) Emissions History
<>Do emissions reported accounting year vary significantly compared previous years explain reasons variations
No, they do not vary significantly. 

 
<>Would like provide additional information relating question provided
Yes 
Total (Scope II III) emissions 2007 reduced 2% 2006 totals Inside figure direct (Scope I) indirect (Scope II) emissions facilities 4% emissions patient use inhaled medicine products (Scope III) 3% travel transport emissions risen 4% significant changes reporting boundaries period work ongoing incorporate inventory newly acquired business units future reports response question 2

 
Question 2(g) Emissions Trading
<>i) Does company facilities covered EU Emissions Trading Scheme
Yes, our company has facilities covered by the EU ETS. (Please answer 2(g)(i)(a), (b) and (c) and 2(g)(ii).)  

 
<>If a) provide details annual allowances awarded company Phase years 1 January 2005 31 December 2007 details allowances allocated Phase II commencing 1 January 2008 cases enter numbers punctuation example enter 2000 instead 2 000 enter allowance Metric Tonnes CO2 1 January 2005 31 December 2005
225954 Metric Tonnes CO2

 
<>1 January 2006 31 December 2006
225954 Metric Tonnes CO2

 
<>1 January 2007 31 December 2007
356918 Metric Tonnes CO2

 
<>b) provide details actual annual emissions facilities covered EU ETS effect 1 January 2005 enter emissions Metric Tonnes CO2 1 January 2005 31 December 2005
160427 Metric Tonnes CO2

 
<>1 January 2006 31 December 2006
180411 Metric Tonnes CO2

 
<>1 January 2007 31 December 2007
158286 Metric Tonnes CO2

 
<>Phase II annual allowances1 January 2008 – 31 December 2008
199300 Metric Tonnes CO2

 
<>1 January 2009 – 31 December 2009
199300 Metric Tonnes CO2

 
<>1 January 2010 – 31 December 2010
199300 Metric Tonnes CO2

 
<>1 January 2011 – 31 December 2011
199300 Metric Tonnes CO2

 
<>1 January 2012 – 31 December 2012
199300 Metric Tonnes CO2

 
<>c) impact company’ s profitability EU ETS
EU ETS visible impact profitability

 
<>ii) company's strategy trading participating regional and/or international trading schemes (eg EU ETS RGGI CCX) Kyoto mechanisms CDM JI projects Explain involvement following EU ETS
managing emissions sites inside EU Emissions Trading Scheme net purchaser allowances second phase scheme EUETS Phase able sell small net surplus allocation proceeds reinvested energy efficiency facilities intend engage strategic permit trading income generating activity

 
<>CDM/JI
mandatory commitments trading schemes intend use CDM/JI voluntary emission reduction credits support strategy reduce emissions successfully operated pilot trial UK business engage party offset project developer order explore practical application offset credit procurement help refine strategic approach offset plans stage use offset make company carbon neutral believe work internal drive reduce emissions far possible

 
<>CCX
involvement

 
<>RGGI
involvement

 
<>Others
involvement

 
<>Would like provide additional information relating question provided
No 

 
Question 2(h) Energy Costs
<>i) identify total costs $ energy consumption fossil fuels electric power want enter number 1 ensure use decimal point (e g 0 3) comma (e g 0 3)
149000000 US$

 
<>ii) percentage total operating costs does represent
0.5 %

 
<>iii) percentage energy costs incurred energy renewable sources

 
<>More details
Comment 2 h iii percentage energy costs incurred energy renewable sources collect information centrally cost renewable energy supply report 23% electricity use globally sourced renewable supplies

 
<>Would like provide additional information relating question provided
No 

 
3 - Performance
Question 3(a) Reduction Plans
<>i) Does company GHG emissions reduction plan place provide details information requested currently plan place explain
Yes, we have a reduction plan in place. (Please proceed to part (ii) ) 

 
<>ii) baseline year emissions reduction plan

 
<>If want information rolling target
reference point reduction objectives average emissions 2001 2002

 
<>iii) emissions reduction targets period targets extend
2006 – 2010 climate change target aims ensure absolute emissions 2010 greater start decade 55% 1990 greenhouse gas emissions business operations continue fall result planned launch Symbicort pMDI 2007 able continue achieve reductions total greenhouse gases (including emissions products) delivered year 2000 committed achieving 2010 target compromising ability provide new inhalation therapies bring benefit patients climate change objectives approved AstraZeneca Board 2005 require substantial efforts business produce 2010 absolute reduction 12% global warming emissions sources pMDIs compared 2005

 
<>iv) activities undertaking reduce emissions renewable energy energy efficiency process modifications offsets sequestration targets set timescales extend
common businesses potential impact climate change arises greenhouse gas emissions energy use facilities house activities various means transport use face additional challenge asthma therapy products use propellant gases potentially contribute ozone depletion global warming AstraZeneca does use large energy relative size recognise importance implementing programmes maximise efficiency minimise emissions progress corporate level building proportion renewable energy energy procurement contracts considering energy impact capital programmes Implicit AstraZeneca Board’ s approval climate change targets understanding improvements required delivered employees working AstraZeneca function location responsible identifying initiatives programmes opportunities contributing global 2010 objectives relevant circumstances needs setting local targets action plans monitoring progress areas reporting progress centrally quarterly basis sites world pursuing energy efficiency projects significant improvements example sites USA collaborated establish local Green Strategy including energy efficiency improvement targets commitment new construction major renovations designed achieve sustainability certification year AZ member Green Building Council current projects track receive certification USGBC program end December 2007 contract signed purchase renewable energy credits windpower covering 2% electricity used sites making EPA Greenpower Partner EPA accepted AZ Energy Star Partner market renewable electricity remains volatile growth demand far outstrips increases supply capacity electricity renewable sources exceeded expectations 23% (221 GWh) global electricity consumption came renewable sources 2007 year supply contract nPower provide majority UK facilities Climate Change Levy exempt electricity years July 2004 successfully extended December 2008 Furthermore headquarters building London environmental science facility Devon large research site Leicestershire electricity needs supplied guaranteed CO2 free renewable resources 41 kte CO2 avoided measures address global warming emissions transport activities selected logistic road haulage companies partner main distribution routes Priority given companies good procedures safety health environment quality management modern trucks efficient engines drivers trained eco safety driving airlines age type fleet taken consideration selection partners Bulk transport final packing products marketing companies reduce demand freight Internally efforts make transport efficient use environmentally friendly packaging options people travel impact local initiatives aimed reducing emissions use cars AstraZeneca’ s sales forces tested bio ethanol powered cars hybrid cars 2005 onwards new cars purchased sales force Brazil refuelled ethanol 'Flex Fuel' end 2007 100 'Flex Fuel' vehicles Swedish fleet (approximately 10%) Fleet Services making progress target reduce greenhouse gas emissions vehicles 12% 9 000 tonnes 2010 selecting new vehicles reflect eco friendly approach company's driving needs Local initiatives Brazil UK Sweden place encourage energy efficient "green" commuting Ozone depletion caused certain halogenated compounds undesirable ozone upper atmosphere acts filter harmful UVB radiation substances cause ozone depletion potent greenhouse gases programme eliminate use facilities residual amounts chlorofluorocarbons (CFCs) hydrochlorofluorocarbons (HCFCs) halons protection refrigeration systems addition AstraZeneca currently uses substances contribute ozone depletion primarily connection metered dose inhalation products prescribed asthmatics working reduce use materials substitution innovative new product designs require propellant gases

 
<>v) investment required achieve targets time period
track separately investments meet environmental objectives investment projects expected stand merits individual business cases basis expect revenue savings improved energy efficiency outweigh investment costs example higher efficiency low emission vehicles lower operating fuel costs tend retain higher resale values end working life Similarly new construction refurbishment existing assets delivered building sustainability features embedded small incremental capital cost offset lower lifetime costs

 
<>vi) emissions reductions associated costs savings achieved date result plan
2007 total GhG emission 1 29million tonnes CO2 equivalent 23% 2001/2 baseline 1 68million tonnes seen key performance metric MWh energy used $million sales value generated fall 133 81 2001 2007 today’ s energy prices equates revenue savings $97 million 2007

 
<>Would like provide additional information relating question provided
No 

 
Question 3(b) Emissions Intensity
<>i) appropriate measurement emissions intensity company
Other 
appropriate indicator emission intensity business sales value measured tonnes CO2 equivalent/US$ million product small drug blister pack weighs information leaflet let packaging mass outputs unhelpful purpose indicator impact/benefit ratios

 
<>Please company’ s emissions intensity figure measurement given want enter number 1 ensure use decimal point (e g 0 3) comma (e g 0 3)
24

 
<>ii) state GHG emissions intensity terms total tonnes CO2 e reported Scope 1 Scope 2 $m turnover EBITDA reporting year Scope 1/ US$millions turnover
14.9

 
<>Scope 2/ US$millions turnover
9.3

 
<>Scope 1/ EBITDA
54.6

 
<>Scope 2/ EBITDA
34.1

 
<>iii) company developed emissions intensity targets
Yes, we have developed emission intensity targets. (Please answer questions (a) and (b) below.) 

 
<>a) answer (iii) yes state emissions intensity targets
2001 corporate target aimed controlling CO2 emissions energy use facilities intensity based target continue use intensity based performance indicators internally track performance delivering current overall climate change objectives current targets expressed absolute emissions emission intensity perceive global climate systems finite carrying capacity anthropogenic emissions irrespective economic activity

 
<>b) answer (iii) yes state reductions emissions intensity achieved targets time period
emissions intensity measured Scopes GhG Protocol decreased 108 44 tonnes/US$ million 2001 2007

 
<>Would like provide additional information relating question provided
No 

 
Question 3(c) Planning
<>Do forecast company’ s future emissions and/or energy use
Yes, we do. (Please answer questions (i) to (iii) below.) 

 
<>i) provide details forecasts summarize methodology used assumptions able quantified forecasts Scope 1 Scope 2 emissions and/or electricity consumption enter numerical data page
projected future emissions 2010 order predict attainment 2006 2010 emissions targets projections use actual figures previous years emissions establish intensity trends incorporate actuarial estimates future corporate sales growth predict base case emissions Overlain estimates information sales forecasts established planned introductions new inhalation products projected attainment emission control activities analysis indicates able exit decade emitting greenhouse gases did start decade 55% did 1990

 
<>ii) factor cost future emissions capital expenditure planning
direct costs emissions small impact overall financial position capital investments account sustainability considerations including indirect operational costs utility costs

 
<>iii) considerations impact investment decisions
significant adjustments capital programme result emissions costs

 
<>Would like provide additional information relating question provided
No 

 
Question 3(c) (i) Planning Forecasted emissions/electricity use Year 1 answers
page gives opportunity numerical forecasts emissions electricity use possible provide emissions forecasts reporting periods Use “ Add additional year figures” button end page enter emission forecasts successive reporting periods Note enter numbers punctuation example use 2000 instead 2 000
<>Please enter accounting period used report GHG emissions details
Start date 01 January 2008End date 31 December 2008

 
<>Forecasted Scope 1 Direct GHG Emissions provide Forecasted Total global Scope 1 emissions Metric Tonnes CO2 e
<>430600 CO2e metric tonnes < text="">

 
<>b Forecasted Total Scope 1 emissions Metric Tonnes CO2 e Annex B countries

 
<>By country Forecasted Scope 1 emissions Metric Tonnes CO2 e individual country Using methodology state emissions forecasts country NB practical list emissions country country basis list countries significant emissions context business combine remainder “ rest world” information format (e g Excel) attach
Country Scope 1 Emissions
(metric tonnes CO2-e)

 
<>Scope 2 Indirect GHG emissions provide c Forecasted total global Scope 2 emissions Metric Tonnes CO2 e
<>272500 CO2e metric tonnes < text="">

 
<>d Forecasted total Scope 2 emissions Metric Tonnes CO2 e Annex B countries

 
<>By country Forecasted Scope 2 emissions Metric Tonnes CO2 e individual country
Country Scope 2 Emissions
(metric tonnes CO2-e)

 
<>Forecasted electricity consumptione Forecasted total global MWh purchased electricity
979200 MWh

 
<>f Forecasted total MWh purchased electricity Annex B countries

 
<>By country – Forecasted MWh purchased electricity individual country
Country

 
<>g Forecasted total global MWh purchased electricity renewable sources
235500 MWh

 
<>h Forecasted total MWh purchased electricity renewable sources Annex B countries

 
<>By country – Forecasted MWh purchased electricity renewable sources individual country
Country

 
<>Would like provide additional information relating question provided
Yes 
forecast data currently broken Annex B country level

 
Question 3(c) (i) Planning Forecasted emissions/electricity use Year 2 answers
page gives opportunity numerical forecasts emissions electricity use possible provide emissions forecasts reporting periods Use “ Add additional year figures” button end page enter emission forecasts successive reporting periods Note enter numbers punctuation example use 2000 instead 2 000
<>Please enter accounting period used report GHG emissions details
Start date 01 January 2009End date 31 December 2009

 
<>Forecasted Scope 1 Direct GHG Emissions provide Forecasted Total global Scope 1 emissions Metric Tonnes CO2 e
<>427200 CO2e metric tonnes < text="">

 
<>b Forecasted Total Scope 1 emissions Metric Tonnes CO2 e Annex B countries

 
<>By country Forecasted Scope 1 emissions Metric Tonnes CO2 e individual country Using methodology state emissions forecasts country NB practical list emissions country country basis list countries significant emissions context business combine remainder “ rest world” information format (e g Excel) attach
Country Scope 1 Emissions
(metric tonnes CO2-e)

 
<>Scope 2 Indirect GHG emissions provide c Forecasted total global Scope 2 emissions Metric Tonnes CO2 e
<>268400 CO2e metric tonnes < text="">

 
<>d Forecasted total Scope 2 emissions Metric Tonnes CO2 e Annex B countries

 
<>By country Forecasted Scope 2 emissions Metric Tonnes CO2 e individual country
Country Scope 2 Emissions
(metric tonnes CO2-e)

 
<>Forecasted electricity consumptione Forecasted total global MWh purchased electricity
983500 MWh

 
<>f Forecasted total MWh purchased electricity Annex B countries

 
<>By country – Forecasted MWh purchased electricity individual country
Country

 
<>g Forecasted total global MWh purchased electricity renewable sources
240500 MWh

 
<>h Forecasted total MWh purchased electricity renewable sources Annex B countries

 
<>By country – Forecasted MWh purchased electricity renewable sources individual country
Country

 
<>Would like provide additional information relating question provided
Yes 
forecast data currently broken Annex B country level

 
Question 3(c) (i) Planning Forecasted emissions/electricity use Year 3 answers
page gives opportunity numerical forecasts emissions electricity use possible provide emissions forecasts reporting periods Use “ Add additional year figures” button end page enter emission forecasts successive reporting periods Note enter numbers punctuation example use 2000 instead 2 000
<>Please enter accounting period used report GHG emissions details
Start date 01 January 2010End date 31 December 2010

 
<>Forecasted Scope 1 Direct GHG Emissions provide Forecasted Total global Scope 1 emissions Metric Tonnes CO2 e
<>423800 CO2e metric tonnes < text="">

 
<>b Forecasted Total Scope 1 emissions Metric Tonnes CO2 e Annex B countries

 
<>By country Forecasted Scope 1 emissions Metric Tonnes CO2 e individual country Using methodology state emissions forecasts country NB practical list emissions country country basis list countries significant emissions context business combine remainder “ rest world” information format (e g Excel) attach
Country Scope 1 Emissions
(metric tonnes CO2-e)

 
<>Scope 2 Indirect GHG emissions provide c Forecasted total global Scope 2 emissions Metric Tonnes CO2 e
<>264400 CO2e metric tonnes < text="">

 
<>d Forecasted total Scope 2 emissions Metric Tonnes CO2 e Annex B countries

 
<>By country Forecasted Scope 2 emissions Metric Tonnes CO2 e individual country
Country Scope 2 Emissions
(metric tonnes CO2-e)

 
<>Forecasted electricity consumptione Forecasted total global MWh purchased electricity
987800 MWh

 
<>f Forecasted total MWh purchased electricity Annex B countries

 
<>By country – Forecasted MWh purchased electricity individual country
Country

 
<>g Forecasted total global MWh purchased electricity renewable sources
245600 MWh

 
<>h Forecasted total MWh purchased electricity renewable sources Annex B countries

 
<>By country – Forecasted MWh purchased electricity renewable sources individual country
Country

 
<>Would like provide additional information relating question provided
Yes 
forecast data currently broken Annex B country level

 
Question 3(c) (i) Planning Forecasted emissions/electricity use Year 4 answers
page gives opportunity numerical forecasts emissions electricity use possible provide emissions forecasts reporting periods Use “ Add additional year figures” button end page enter emission forecasts successive reporting periods Note enter numbers punctuation example use 2000 instead 2 000
<>Please enter accounting period used report GHG emissions details
Start date 01 January 2011End date 31 December 2011

 
<>Forecasted Scope 1 Direct GHG Emissions provide Forecasted Total global Scope 1 emissions Metric Tonnes CO2 e
<>421300 CO2e metric tonnes < text="">

 
<>b Forecasted Total Scope 1 emissions Metric Tonnes CO2 e Annex B countries

 
<>By country Forecasted Scope 1 emissions Metric Tonnes CO2 e individual country Using methodology state emissions forecasts country NB practical list emissions country country basis list countries significant emissions context business combine remainder “ rest world” information format (e g Excel) attach
Country Scope 1 Emissions
(metric tonnes CO2-e)

 
<>Scope 2 Indirect GHG emissions provide c Forecasted total global Scope 2 emissions Metric Tonnes CO2 e
<>260400 CO2e metric tonnes < text="">

 
<>d Forecasted total Scope 2 emissions Metric Tonnes CO2 e Annex B countries

 
<>By country Forecasted Scope 2 emissions Metric Tonnes CO2 e individual country
Country Scope 2 Emissions
(metric tonnes CO2-e)

 
<>Forecasted electricity consumptione Forecasted total global MWh purchased electricity
992200 MWh

 
<>f Forecasted total MWh purchased electricity Annex B countries

 
<>By country – Forecasted MWh purchased electricity individual country
Country

 
<>g Forecasted total global MWh purchased electricity renewable sources
250900 MWh

 
<>h Forecasted total MWh purchased electricity renewable sources Annex B countries

 
<>By country – Forecasted MWh purchased electricity renewable sources individual country
Country

 
<>Would like provide additional information relating question provided
Yes 
forecast data currently broken Annex B country level

 
Question 3(c) (i) Planning Forecasted emissions/electricity use Year 5 answers
page gives opportunity numerical forecasts emissions electricity use possible provide emissions forecasts reporting periods Use “ Add additional year figures” button end page enter emission forecasts successive reporting periods Note enter numbers punctuation example use 2000 instead 2 000
<>Please enter accounting period used report GHG emissions details
Start date 01 January 2012End date 31 December 2012

 
<>Forecasted Scope 1 Direct GHG Emissions provide Forecasted Total global Scope 1 emissions Metric Tonnes CO2 e
<>418800 CO2e metric tonnes < text="">

 
<>b Forecasted Total Scope 1 emissions Metric Tonnes CO2 e Annex B countries

 
<>By country Forecasted Scope 1 emissions Metric Tonnes CO2 e individual country Using methodology state emissions forecasts country NB practical list emissions country country basis list countries significant emissions context business combine remainder “ rest world” information format (e g Excel) attach
Country Scope 1 Emissions
(metric tonnes CO2-e)

 
<>Scope 2 Indirect GHG emissions provide c Forecasted total global Scope 2 emissions Metric Tonnes CO2 e
<>256500 CO2e metric tonnes < text="">

 
<>d Forecasted total Scope 2 emissions Metric Tonnes CO2 e Annex B countries

 
<>By country Forecasted Scope 2 emissions Metric Tonnes CO2 e individual country
Country Scope 2 Emissions
(metric tonnes CO2-e)

 
<>Forecasted electricity consumptione Forecasted total global MWh purchased electricity
996500 MWh

 
<>f Forecasted total MWh purchased electricity Annex B countries

 
<>By country – Forecasted MWh purchased electricity individual country
Country

 
<>g Forecasted total global MWh purchased electricity renewable sources
256200 MWh

 
<>h Forecasted total MWh purchased electricity renewable sources Annex B countries

 
<>By country – Forecasted MWh purchased electricity renewable sources individual country
Country

 
<>Would like provide additional information relating question provided
Yes 
forecast data currently broken Annex B country level

 
4 - Governance
Question 4(a) Responsibility
<>Does Board Committee executive body overall responsibility climate change state overall responsibility climate change managed answer parts (i) (ii)
Yes, an executive body does have overall responsibility for climate change. 

 
<>i) Board Committee executive body overall responsibility climate change
AstraZeneca Board collective responsibility business strategy related environment including climate change Specific action planning climate change included Corporate Responsibility (CR) strategy Non Executive Director responsibility overseeing implementation strategy Company Senior Executive Team senior managers accountable CR management areas based global framework taking account national functional site issues priorities Individually AstraZeneca responsibility integrate CR considerations day day decision making actions behaviours 2007 strengthened leadership governance area establishment new function Group Public Affairs leading development strategic approach aligning tactical delivery new group works closely Global Compliance group senior business functional leaders AstraZeneca ensure appropriate systems place identifying risks opportunities associated corporate responsibility effective frameworks managing monitoring progress objectives ensuring compliance relevant policies standards

 
<>ii) mechanism Board executive body reviews company’ s progress status regarding climate change
company’ s objectives climate change framed Corporate Safety Health Environment objectives embedded Corporate Responsibility Priority Action Plan ensures inclusion Senior Executive Team (SET) Business Performance Management (BPM) framework targets deliverables associated high level objectives integrated relevant functional BPM framework appropriately included individual performance objectives Progress objectives levels reviewed year including quarterly review individual business function action plans SET level review SET scorecard AstraZeneca Board

 
<>Would like provide additional information relating question provided
No 

 
Question 4(b) Individual Performance
<>Do assess provide incentive mechanisms individual management climate change issues including attainment GHG targets provide details
Yes, we do. 
Remuneration staff including senior management assessed basis attainment targets Management climate change issues incentivised extent climate change objectives included process environment related CR objectives reflects performance Dow Jones Sustainability Index specific performance measure included Senior Executive Team Business Performance Management (BPM) framework

 
<>Would like provide additional information relating question provided
No 

 
Question 4(c) Communications
<>Please indicate publish information risks opportunities presented company climate change details GHG emissions plans reduce emissions following communications i) company’ s Annual Report statutory filings
Yes 
Link pdf download http //www astrazeneca annualreports com/annualreport2007/Downloads/AZ_Annual_Report_07 pdf

 
<>ii) formal communications shareholders external parties
Yes 
Responses benchmarking activities CDP Dow Jones Sustainability Index

 
<>iii) voluntary communications Corporate Social Responsibility reporting
Yes 
Link AZ Responsibility webpages Climate Change Global Warming http //www astrazeneca com/article/511607 aspxhttp //www astrazeneca com/article/11134 aspx

 
<>Would like provide additional information relating question provided
No 

 
Question 4(d) Public Policy
<>Do engage policymakers possible responses climate change including taxation regulation carbon trading provide details
Yes 
provide representation various industry association working groups public consultations principally · UK Chemical Industries Association Emissions Trading Working Group· International Chamber Commerce (ICC) Environment & Energy Commission Climate Task Force· UK Confederation British Industry Emissions Trading Working Group· ICC UK DBERR DEFRA liaison group

 
<>Would like provide additional information relating question provided
No 

 
We have upgraded our website login. If you have registered to view CDP responses before December 23, please re-register and we will issue new login details.
  Join the CDP LinkedIn group Follow @cdp on Twitter          Subscribe to receive our monthly newsletter
  Connect with us          Newsletter
   
 
 
  © 2014 CARBON DISCLOSURE PROJECT, Registered Charity no. 1122330.
A company limited by guarantee registered in England no. 05013650